RenovoRx, Inc. (RNXT): Price and Financial Metrics
RNXT Price/Volume Stats
| Current price | $1.21 | 52-week high | $3.29 |
| Prev. close | $1.21 | 52-week low | $0.53 |
| Day low | $1.21 | Volume | 164 |
| Day high | $1.21 | Avg. volume | 57,360 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $1.35 | Market Cap | 20.41M |
RNXT Stock Price Chart Interactive Chart >
RenovoRx, Inc. (RNXT) Company Bio
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Latest RNXT News From Around the Web
Below are the latest news stories about RENOVORX INC that investors may wish to consider to help them evaluate RNXT as an investment opportunity.
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerLOS ALTOS, Calif., December 21, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial. The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma |
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingLOS ALTOS, Calif., December 19, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah. The abstract will highlight the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perf |
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy PlatformLOS ALTOS, Calif., December 13, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The Company already holds a strong intellectual property portfolio with 9 issued patents and 9 pending patents |
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.LOS ALTOS, Calif., November 16, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of E |
RenovoRx Reports Third Quarter 2023 Financial Results and Operational HighlightsLOS ALTOS, Calif., November 14, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023. |
RNXT Price Returns
| 1-mo | -12.32% |
| 3-mo | 15.24% |
| 6-mo | 17.48% |
| 1-year | -61.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.16% |
| 2023 | -2.55% |
| 2022 | -51.45% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...